Beckman Coulter's CEO John Wareham talks to The Wall Street Transcript.

Business Editors

NEW YORK--(BUSINESS WIRE)--Oct. 3, 2000

The Wall Street Transcript has published an in-depth interview with John Wareham, CEO of Beckman Coulter (NYSE:BEC), in which he talks at length about the company's future.

The entire 2,200-word interview is available free online at http://www.twst.com/ceos.htm.

Wareham gives an overview of the company. "We simplify and automate processes for biomedical testing. Our big customers are hospitals, research laboratories, pharmaceutical and biotechnology companies. When we talk about biomedical testing, one of our largest businesses is testing blood. I'm sure you've had your blood taken and you've gotten test results. We make the systems that automate testing and produce those results."

Wareham explains, "We can perform 100% of the routine testing in the hospital; that was one of the results of putting Beckman and Coulter together, along with some of the other acquisitions we did in the mid-1990s. The goal was to provide all of the routine testing, so that we could work the entire testing process in the lab."

Looking forward, Wareham states, "Another trend we see is that new therapeutic treatments will probably be accompanied by more diagnostic testing that enables you to stratify patients and predict the utility of the therapy. The whole outgrowth of DNA mapping is a promising area. You may have heard of SNP (single nucleotide polymorphism) analysis, where you can characterize people; that's a new technology. We'll be able to tell more about patients before therapy --- that's a field called theranostics. So we see that as a trend in maybe the next 10 years or so."

This interview is part of a 288-page UBS Warburg LLC Global Life Sciences Conference Issue available at http://www.twst.com/info/info181.htm or by calling [phone].

The Wall Street Transcript is a premier weekly investment publication serving serious long-term investors for over 37 years.

The Wall Street Transcript has launched a new free service where investors can ask Beckman Coulter (or any public company) a question at http://www.qawire.com.

The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call [phone].